| Short Squeeze Potential in Arena as Vivus Panel Date Looms Ruthanne Williams Roussel submits:As expected, and as management discussed as a possibility a few weeks ago on the Q1 conference call, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review Arena Pharmaceuticals (ARNA)'s weight-loss drug candidate lorcaserin at its already scheduled Sept. 16 meeting. We rate this news as good. In the small-cap world, it is always especially reassuring when outside agencies behave as management expects them to. While lorcaserin's cardiovascular safety has been extensively studied and independently reviewed, we still were never in the camp that believed that this might give lorcaserin some sort of free pass to FDA approval with no further review. The PDUFA (approval decision) date for lorcaserin is in late October.Complete Story » seekingalpha.com |
Yet Another Pipeline Setback for Pfizer Zacks.com submits: Recently, Pfizer Inc. (PFE) halted studies being conducted with pipeline candidate tanezumab, which is being developed for the treatment of patients suffering from osteoarthritis. The global suspension comes in the wake of the FDA's request to the pharma major to stop the osteoarthritis clinical program. The request was based on reports of the disease becoming more severe in a few patients who were treated with tanezumab. The increased severity led to joint replacement.Complete Story » seekingalpha.com |
Cord Blood America CEO Interview Details Company's 2010 Achievements (PR Newswire) Cord Blood America, Inc. said today that its co-founder and CEO, Matthew Schissler, reviewed the Company's progress in 2010, saying it is "on track" to accomplish all of its goals, in an interview with analyst Francis Gaskins. Â us.rd.yahoo.com |
Cigna Seeks Health Abroad Cigna is expanding overseas, leading a push by health insurers to find growth amid uncertainties at home. online.wsj.com |
New Study Questions Value of Expanded Genetic Testing for Cystic Fibrosis [PR Newswire] - Testing for genetic mutations beyond those medically recommended is unlikely to prevent the birth of children with classic cystic fibrosis and may detect mutations causing only mild disease, according to a study published online in Genetics in Medicine, the official publication of the American College of Medical Genetics . The findings raise the possibility that expanded panels may promote ill-informed decisions and anxiety for physicians and couples seeking testing to determine their risk of passing the disease to their children. us.rd.yahoo.com |